Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Aggregated Volume: 903.354 shares.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details an increase in the notional interest in Ordinary Shares for Mr. D S Redfern (Chief Strategy Officer) resulting from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of an insider share transaction.
Key Facts for Investor Verification
- The filing is a transaction notification for Mr. D S Redfern, Chief Strategy Officer.
- The transaction involved the re-investment of dividends into 903.354 shares at £16.285 each.
- The transaction date was July 14, 2016.
- This document does not contain quarterly or annual financial performance data.